Antiemetic efficacy of high-dose metoclopramide

Randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting

Richard J. Gralla, L. M. Itri, S. E. Pisko, A. E. Squillante, D. P. Kelsen, D. W. Braun, L. A. Bordin, T. J. Braun, C. W. Young

Research output: Contribution to journalArticle

565 Citations (Scopus)

Abstract

In a study of the effectiveness of high intravenous doses of metoclopramide as an antiemetic, 41 patients with advanced cancer who were being treated with cisplatin were entered into two double-blind trials. In the first trial patients were randomly assigned to receive either metoclopramide or placebo, and in the second trial they received either metoclopramide or prochlorperazine. Patients given metoclopramide had significantly fewer episodes of emesis than patients given placebo (medians, 1.0 vs. 10.5; P = 0.001) or prochlorperazine (medians, 1.5 vs. 12.0; P = 0.005). Metoclopramide was superior to placebo and to prochlorperazine in reducing the volume of emesis (P = 0.001 and P = 0.002, respectively) and was more effective than placebo in shortening the duration of nausea (P = 0.042) and vomiting (P = 0.028). Side effects from metoclopramide were minor, with mild sedation frequently observed; one patient had a brief extrapyramidal reaction. We conclude that metoclopramide in high intravenous doses has greater antiemetic activity than placebo or prochlorperazine in patients receiving cisplatin chemotherapy.

Original languageEnglish (US)
Pages (from-to)905-909
Number of pages5
JournalNew England Journal of Medicine
Volume305
Issue number16
StatePublished - 1981
Externally publishedYes

Fingerprint

Prochlorperazine
Metoclopramide
Antiemetics
Nausea
Vomiting
Placebos
Drug Therapy
Cisplatin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Antiemetic efficacy of high-dose metoclopramide : Randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. / Gralla, Richard J.; Itri, L. M.; Pisko, S. E.; Squillante, A. E.; Kelsen, D. P.; Braun, D. W.; Bordin, L. A.; Braun, T. J.; Young, C. W.

In: New England Journal of Medicine, Vol. 305, No. 16, 1981, p. 905-909.

Research output: Contribution to journalArticle

Gralla, RJ, Itri, LM, Pisko, SE, Squillante, AE, Kelsen, DP, Braun, DW, Bordin, LA, Braun, TJ & Young, CW 1981, 'Antiemetic efficacy of high-dose metoclopramide: Randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting', New England Journal of Medicine, vol. 305, no. 16, pp. 905-909.
Gralla, Richard J. ; Itri, L. M. ; Pisko, S. E. ; Squillante, A. E. ; Kelsen, D. P. ; Braun, D. W. ; Bordin, L. A. ; Braun, T. J. ; Young, C. W. / Antiemetic efficacy of high-dose metoclopramide : Randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. In: New England Journal of Medicine. 1981 ; Vol. 305, No. 16. pp. 905-909.
@article{8fff653f659248b3a0da8e069c4226a5,
title = "Antiemetic efficacy of high-dose metoclopramide: Randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting",
abstract = "In a study of the effectiveness of high intravenous doses of metoclopramide as an antiemetic, 41 patients with advanced cancer who were being treated with cisplatin were entered into two double-blind trials. In the first trial patients were randomly assigned to receive either metoclopramide or placebo, and in the second trial they received either metoclopramide or prochlorperazine. Patients given metoclopramide had significantly fewer episodes of emesis than patients given placebo (medians, 1.0 vs. 10.5; P = 0.001) or prochlorperazine (medians, 1.5 vs. 12.0; P = 0.005). Metoclopramide was superior to placebo and to prochlorperazine in reducing the volume of emesis (P = 0.001 and P = 0.002, respectively) and was more effective than placebo in shortening the duration of nausea (P = 0.042) and vomiting (P = 0.028). Side effects from metoclopramide were minor, with mild sedation frequently observed; one patient had a brief extrapyramidal reaction. We conclude that metoclopramide in high intravenous doses has greater antiemetic activity than placebo or prochlorperazine in patients receiving cisplatin chemotherapy.",
author = "Gralla, {Richard J.} and Itri, {L. M.} and Pisko, {S. E.} and Squillante, {A. E.} and Kelsen, {D. P.} and Braun, {D. W.} and Bordin, {L. A.} and Braun, {T. J.} and Young, {C. W.}",
year = "1981",
language = "English (US)",
volume = "305",
pages = "905--909",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "16",

}

TY - JOUR

T1 - Antiemetic efficacy of high-dose metoclopramide

T2 - Randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting

AU - Gralla, Richard J.

AU - Itri, L. M.

AU - Pisko, S. E.

AU - Squillante, A. E.

AU - Kelsen, D. P.

AU - Braun, D. W.

AU - Bordin, L. A.

AU - Braun, T. J.

AU - Young, C. W.

PY - 1981

Y1 - 1981

N2 - In a study of the effectiveness of high intravenous doses of metoclopramide as an antiemetic, 41 patients with advanced cancer who were being treated with cisplatin were entered into two double-blind trials. In the first trial patients were randomly assigned to receive either metoclopramide or placebo, and in the second trial they received either metoclopramide or prochlorperazine. Patients given metoclopramide had significantly fewer episodes of emesis than patients given placebo (medians, 1.0 vs. 10.5; P = 0.001) or prochlorperazine (medians, 1.5 vs. 12.0; P = 0.005). Metoclopramide was superior to placebo and to prochlorperazine in reducing the volume of emesis (P = 0.001 and P = 0.002, respectively) and was more effective than placebo in shortening the duration of nausea (P = 0.042) and vomiting (P = 0.028). Side effects from metoclopramide were minor, with mild sedation frequently observed; one patient had a brief extrapyramidal reaction. We conclude that metoclopramide in high intravenous doses has greater antiemetic activity than placebo or prochlorperazine in patients receiving cisplatin chemotherapy.

AB - In a study of the effectiveness of high intravenous doses of metoclopramide as an antiemetic, 41 patients with advanced cancer who were being treated with cisplatin were entered into two double-blind trials. In the first trial patients were randomly assigned to receive either metoclopramide or placebo, and in the second trial they received either metoclopramide or prochlorperazine. Patients given metoclopramide had significantly fewer episodes of emesis than patients given placebo (medians, 1.0 vs. 10.5; P = 0.001) or prochlorperazine (medians, 1.5 vs. 12.0; P = 0.005). Metoclopramide was superior to placebo and to prochlorperazine in reducing the volume of emesis (P = 0.001 and P = 0.002, respectively) and was more effective than placebo in shortening the duration of nausea (P = 0.042) and vomiting (P = 0.028). Side effects from metoclopramide were minor, with mild sedation frequently observed; one patient had a brief extrapyramidal reaction. We conclude that metoclopramide in high intravenous doses has greater antiemetic activity than placebo or prochlorperazine in patients receiving cisplatin chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0019502642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019502642&partnerID=8YFLogxK

M3 - Article

VL - 305

SP - 905

EP - 909

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 16

ER -